Aptose biosciences inc. (APTO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Cash flows from/(used in) operating activities:
Net loss for the period

-11,526

-7,709

-6,844

-6,218

-5,506

-6,261

-5,531

-10,262

-6,814

-

-

Items not involving cash:
Stock-based compensation

4,401

562

504

568

662

581

952

515

2,228

-

-

Shares issued to Aspire Capital as commitment fees

-

-

-

360

-

-

-

600

-

-

-

Depreciation and amortization

41

37

33

53

29

23

29

19

16

-

-

Amortization of right-of-use assets

115

115

115

107

124

-

-

-

-

-

-

Interest on lease liabilities

18

21

22

23

24

-

-

-

-

-

-

Unrealized foreign exchange (gain)/loss

15

25

-5

1

2

-24

21

4

-26

-

-

Accrued interest on investments

60

-

58

19

-

-

-

-

-

-

-

Change in operating working capital:
Prepaid expenses

-139

740

-437

183

-107

326

-68

139

-73

-

-

Other assets

-24

32

-59

73

-6

-38

-66

108

23

-

-

Operating lease payments

131

126

126

120

99

-

-

-

-

-

-

Accounts payable

57

786

-66

70

-145

128

41

784

-227

-

-

Accrued liabilities

-1,174

837

735

164

-74

291

-72

-588

667

-

-

Cash used in operating activities

-8,111

-6,231

-5,184

-5,269

-4,874

-5,502

-4,468

-9,183

-4,054

-

-

Cash flows from financing activities:
Offering costs paid

-

-

-

142

-

1

7

2

5

-

-

Issuance of common shares under exercise of stock options

436

-

17

19

-

-

-

183

-

-

-

Cash provided by financing activities

436

73,640

17

23,613

6,178

5,839

1,608

11,569

8,855

-

-

Cash flows from/(used in) investing activities:
Acquisition of investments, net

12,411

-

1,000

8,000

-

-

-

-250

-

-

-

Purchase of property and equipment

16

10

42

26

24

177

28

100

24

-

-

Cash used in investing activities

-12,427

-8,278

-1,042

-8,026

-24

-86

-28

150

-24

-

-

Effect of exchange rate fluctuations on cash and cash equivalents held

14

25

-3

-1

2

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

-20,088

59,156

-6,212

10,317

1,282

243

-2,888

2,536

4,777

-

-

Net loss for the period

-

-

-

-

-

-

-5,522

-

-

-2,640

-2,441

Stock-based compensation

-

-

-

-

-

-

952

-

-

156

449

Shares issued to Aspire Capital as commitment fees (note 6(a)(iii))

-

-

-

-

-

-

0

-

-

0

0

Depreciation and amortization

-

-

-

-

-

-

29

-

-

20

23

Interest income

-

-

-

-

-

-

80

-

-

21

11

Unrealized foreign exchange (loss) gain

-

-

-

-

-

-

-28

-

-

-48

-29

Change in non-cash operating working capital (note 8)

-

-

-

-

-

-

-101

-

-

-442

631

Cash used in operating activities

-

-

-

-

-

-

-4,548

-

-

-2,091

-2,640

Issuance of common shares under the 2018 ATM, net of issuance costs (note 6(a)(i))

-

-

-

-

-

-

1,572

-

-

0

0

Issuance of common shares under Share Purchase Agreement (note 6(a)(ii))

-

-

-

-

-

-

0

-

-

0

0

Issuance of common shares under the ATM, net of issuance costs (note 6(a)(iv))

-

-

-

-

-

-

0

-

-

1,999

4,528

Issuance of common shares upon exercise of stock options (note 7)

-

-

-

-

-

-

36

-

-

0

0

Cash provided by financing activities

-

-

-

-

-

-

1,608

-

-

1,999

4,528

Maturity (acquisition) of investments

-

-

-

-

-

-

0

-

-

-9

-2,985

Purchase of property and equipment

-

-

-

-

-

-

28

-

-

0

0

Interest received

-

-

-

-

-

-

80

-

-

21

11

Cash provided by (used in) investing activities

-

-

-

-

-

-

52

-

-

12

-2,974

Effect of exchange rate fluctuations on cash and cash equivalents held

-

-

-

-

-

-

0

-

-

48

29

Increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-2,888

-

-

-32

-1,057

The 2018 Purchase Agreement [Member]
Issuance of common shares

-

-

-

4,000

-

-

-

-

-

-

-

The 2017 Purchase Agreement [Member]
Issuance of common shares

-

-

-

-

-

-

0

6,140

8,860

-

-

The 2018 ATM Offering [Member]
Issuance of common shares

-

-

-

-

-

-

-

5,248

-

-

-

Issuance of common shares

-

-5

0

5

178

-

-

-

-

-

-

The 2019 Share Purchase Agreement [Member]
Issuance of common shares

-

-

-

-

6,000

-

-

-

-

-

-

Public Offering [Member]
Proceeds from Issuance of Common Stock

-

-

-

19,736

-

-

-

-

-

-

-